RSSCOMPANIES: INDUSTRIES:
Biotechnology Jobs & Careers Search
Find your next job in Biotechnology. Search Biotechnology jobs from thousands of job and career search sites.
A search engine for jobs with a different approach to job and career searches. In one simple search, job
seekers get free access to millions of employment opportunities from thousands of websites. Find your next job in Biotechnology today.
CT Atlantic AG Announces Appointment of Michael Höcker to CEO
CT Atlantic AG, a biotechnology company focused on cancer treatment by human-derived antibodies, announced the appointment of Michael Höcker to CEO. In addition, Cara Lerner has been appointed to ...
Generex Provides Positive Update on Generex Oral-lyn Pivotal Phase III Trial
Generex Biotechnology Corporation announced that it has now achieved 75% of the required number of per-protocol completers in its ongoing six month pivotal global Phase III study of Generex ...
Information on the risks and benefits of pesticides does not reach consumers
Consumers know little about pesticide residues in food. They do show considerable interest in this subject but dont think they are sufficiently well informed. This is the outcome of representative ...
One molecule, many more insulin-producing cells to treat diabetes, says Pitt team
With a single stimulatory molecule, human insulin-producing beta cell replication can be sustained for at least four weeks in a mouse model of diabetes, according to researchers at the University of ...
Aptuit and Siena Biotech Announce Strategic Relationship in Italy
Aptuit, Inc., and Siena Biotech S.p.A, announced a strategic partnership in which Siena Biotech will take a minority stake in Aptuits Italian operations in Verona, Italy, and Aptuit will become a ...
Bayer increases sales and earnings in the second quarter
The Bayer Group once again achieved gains in sales and earnings in the second quarter of 2010. "MaterialScience has left the crisis behind and saw business expand more strongly than expected. Volumes ...
SynCo Bio Partners and Versartis Expand Collaboration as Lead Product Enters into Clinical Trials
SynCo Bio Partners announced an extension of its collaboration with Versartis, Inc. following the recent initiation of a Phase 1 clinical trial in type 2 diabetes mellitus (T2DM) patients with ...
Plasma technology for solvent-free utility wood
In order to raise the competitiveness of wood compared to other materials, it is necessary to develop a cost-efficient method of wood protection which is free of toxic chemicals and nevertheless ...
Ablynx announces change in management
Ablynx announced that its Chief Scientific Officer, Debbie Law, has resigned from her position at Ablynx, effective 31 August, as she will be returning to the USA with her family for personal ...
Breaching the blood-brain barrier to create powerful new tools for fighting cancer
One of the human body's most powerful defensive tools, the blood-brain barrier is a chemical labyrinth that prevents toxins and viruses in the bloodstream from reaching the brain. This foolproof ...
Engineered coral pigment helps scientists to observe protein movement
Scientists in Southampton, UK, and Ulm and Karlsruhe in Germany have shown that a variant form of a fluorescent protein (FP) originally isolated from a reef coral has excellent properties as a marker ...
Exact Sciences Obtains Exclusive License to Oncomethylome Sciences' DNA Methylation Biomarkers
Exact Sciences Corp. and OncoMethylome Sciences S.A. announced that they have entered into a license agreement under which Exact Sciences has obtained exclusive, worldwide rights to up to two ...
BD Board of Directors Elects Christopher Jones
BD (Becton, Dickinson and Company) announced that it has elected Christopher Jones to its Board of Directors.Mr. Jones, 55, is the former Chief Executive Officer of JWT Worldwide (previously known as ...
Bio Nano Consulting signs agreement with The School of Pharmacy, University of London
Bio Nano Consulting (BNC) announced the signing of a service level agreement (SLA) with The School of Pharmacy, University of London. This latest SLA enables BNC to offer an expanded service offering ...
Once bitten, twice shy - a temperature switch triggers aversive memory
Prevention is better than cure and avoidance strategies often help to save us from adversity. A child, for example, quickly learns not to touch a hot stove once it burned its fingers. Avoidance ...
Merck KGaA: FDA Grants Priority Review to Cladribine Tablets for the Treatment of Relapsing Forms of Multiple Sclerosis
Merck KGaA announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Cladribine Tablets as a therapy for relapsing forms of multiple ...
ProtAffin AG signs manufacturing contract for PA401 with CMC Biologics A/S
ProtAffin AG announced it has signed a manufacturing contract with CMC Biologics Danish operations, located in Copenhagen, Denmark for manufacture of its lead product PA401 for the treatment of ...
Cerenis Therapeutics raises 40 million in series C financing
Cerenis Therapeutics SA announced it has raised 40 million in the first close of its series C financing. In this round 20 million came from the Fund for Strategic Investment (FSI) with an ...
Max Planck Innovation awards license for actin marker LifeAct
Max Planck Innovation GmbH, the technology transfer organization of the Max Planck Society, has awarded an exclusive license for LifeAct to ibidi GmbH, a provider of cell analysis products, located ...
Preventing heart problems while keeping a cool head
Cholesterol influences the health of our hearts and blood vessels. Conventional treatment attempts to reduce the level of "bad" cholesterol, LDL cholesterol, in the blood plasma. The opposite ...
Bionity.COM News
The latest news about trends and developments in the biotech, pharma and life science industries
New biodegradable compound facilitates bone regeneration in cases of substantial loss
Bones have a capacity to regenerate themselves after suffering partial damage. However, it is really quite another thing when a serious break or tumour lesion occurs and the loss of tissue is substantial. Today these cases are treated with various kinds o
Research of cell movements in developing frogs reveals new twists in human genetic disease
Mutations in a gene known as "Fritz" may be responsible for causing human genetic disorders such as Bardet-Biedl syndrome, University of Texas at Austin developmental biologist John Wallingford and Duke University human geneticist and cell biologist Nicho
Study finds diet and alcohol alter epigenetics of breast cancer
Researchers from Brown University and the University of California have shown that the epigenetic profiles of breast tumors are related to patient diet and alcohol use as well as tumor size.
New 'armor' developed to avoid infection from AIDS virus
The doors are closing on the AIDS virus. A study by the Consejo Superior de Investigaciones Cientνficas has developed a method of attack against the AIDS virus The method involves creating a prevention system, i.e. an "armor" in the cells that are likely
UCI immunological study finds earlier way to diagnose axon and neuron degeneration in MS
UCI immunologists have found that testing for increased levels of antibodies that inhibit energy production in neurons can detect axon and neuron degeneration in multiple sclerosis earlier than existing diagnostic tools.
Calcium supplements play an important role in maintaining bone health
A broad range of scientific research has demonstrated that an adequate intake of calcium plays an important role in building and maintaining optimum bone mass, and a recent meta-analysis published online in the British Medical Journal should not cause con
Decontaminating dangerous drywall
A nanomaterial originally developed to fight toxic waste is now helping reduce debilitating fumes in homes with corrosive drywall.
UC Davis study finds worse mental health associated with worse pain in osteoarthritis
How much pain osteoarthritis sufferers feel is directly related to their mental health, a new study by researchers at UC Davis School of Medicine has found. In the study, people with better mental health felt less pain, and people with worse mental health
Reforestation projects capture more carbon than industrial plantations, reveals new research
Australian scientists researching environmental restoration projects have found that the reforestation of damaged rainforests is more efficient at capturing carbon than controversial softwood monoculture plantations. The research, published in Ecological
30 million women to benefit from health reform law
Thirty million women will benefit from the new health reform law over the next decade, either through new or strengthened insurance coverage, according to a new report from The Commonwealth Fund. The law will stabilize and reverse the growing exposure to
TylenolΒ? - Pain Relief
Video Results
Nutraloid Labs Inc. Conducts Voluntary Nationwide Recall of Two Dietary Supplements Found to Contain Undeclared Drug Ingredient
Nutraloid Labs Inc. announced today that it is conducting a voluntary nationwide recall of two dietary supplement products sold under the names: ejaculoid XXTREME and stimuloid II. Nutraloid Labs Inc. has been informed by representatives of the Food and D
Specialty Farms, LLC Recalls Organic Alfalfa Sprouts Blend and Organic Sprout Salad in the North Eastern United States Because of Possible Health Risk
Specialty-Farms, LLC is voluntarily recalling Specialty Farms brand Organic Alfalfa Sprouts Blend and Organic Sprout Salad, as noted below. These items both have a "sell-by date of 7/26/2010" and are net weight 4 ounces in plastic containers...
Ancient reptiles 'make tracks'
A new discovery of fossilized footprints reveals when reptiles first conquered dry land.
Specialty Farms, LLC Expands Recall of Organic Alfalfa Sprouts Blend and Organic Sprout Salad in the North Eastern United States Because of Possible Health Risk
Specialty Farms is voluntarily recalling certain Alfalfa sprout products with a best if sold by date of β8/3/2010β and β8/1/2010β that has the potential to be contaminated with Listeria Monocytogenes (LM). Listeria Monocytogenes is an organism whi
Unexpected viral 'fossils' found in vertebrate genomes
Over millions of years, retroviruses, which insert their genetic material into the host genome as part of their replication, have left behind bits of their genetic material in vertebrate genomes. In a recent study, published July 29 in the open-access jou
Snake venom studies yield insights for development of therapies for heart disease and cancer
Researchers seeking to learn more about stroke by studying how the body responds to toxins in snake venom are this week releasing new findings that they hope will aid in the development of therapies for heart disease and, surprisingly, cancer.
TNF blockers may increase the risk of malignancy in children
The Food and Drug Administration received reports of malignancies in children using tumor necrosis factor a (TNF) blockers, raising concerns of an associated risk and prompting an investigation. Researchers from the FDA set out to identify all reports of
Mechanism uncovered behind Salmonella virulence and drug susceptibility
Researchers have discovered a novel mechanism in Salmonella that affects is virulence and its susceptibility to antibiotics. The mechanism changes the bacteria's production of proteins in a previously unheard of manner. It allows Salmonella to selectivel
Some trees 'farm' bacteria to help supply nutrients
Some trees growing in nutrient-poor forest soil may get what they need by cultivating specific root microbes to create compounds they require. These microbes are exceptionally efficient at turning inorganic minerals into nutrients that the trees can use.
GeneRef Combined News
GeneRef - Science News, Genomics, Bioinformatics, Nanotechnology, A Global Resource
Charles River Laboratories (Massachusetts) and WuXi PharmaTech Co., Ltd. $1.6 Billion Deal Ended After Opposition
WILMINGTON, Mass., Jul 29, 2010 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. /quotes/comstock/13*!crl/quotes/nls/crl (CRL 34.00, 2.05, 6.42%) , a leading global provider of research models and associated services and of preclinical drug development services, today announced that it has mutually agreed with WuXi PharmaTech (Cayman) Inc. /quotes/comstock/13*!wx/quotes/nls/wx ...
Sanofi-Aventis (France) CEO Targeting Everything But Blockbusters
TRENTON, N.J. -- After 20 months running drugmaker Sanofi-Aventis SA, Chris Viehbacher wants to end the roller coaster of revenue peaks and valleys as blockbuster drugs climb to billions in sales and suddenly plummet when generic competition hits.
Actient Pharmaceuticals LLC Inks Deal with UCB SA for Marketed Drugs with Global Sales of $53M
CHICAGO--(BUSINESS WIRE)--GTCR, one of the countrys leading private equity firms, announced today that Actient Pharmaceuticals, LLC has successfully completed a transaction to license and acquire six pharmaceutical products from UCB, Inc., a subsidiary of UCB SA, an international biopharmaceutical company based in Brussels, Belgium.The acquisition of the six on-market products is the first...
Senate Panel Votes To Restrict Drug Patent Deals
WASHINGTON (Dow Jones)--The Senate Appropriations Committee on Thursday approved a measure that would restrict the use of controversial settlements in which brand-name drug companies pay their generic competitors to drop patent challenges that could lead to early entry of generic drugs.
Orexigen Therapeutics, Inc. Obesity Pill Shows Promise in Phase III Study; Stock Rises 11.37% at 10:17AM EDT
SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced that results from its COR-I trial of Contrave were published online today in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration...
FDA Warns About Pneumonia Caused By Cubist Pharmaceuticals, Inc.'s Antibiotic Cubicin
WASHINGTON July 29 (Reuters) - U.S. health officials warned Thursday about the risk of pneumonia with Cubist Pharmaceuticals Inc's (CBST.O) flagship antibiotic.
Risk of MI May Go Up With Calcium Supplements, University of Auckland Study
MedPage Today -- Calcium supplementation appears to increase the risk of myocardial infarction, a meta-analysis showed.
Ruling May Force To Halt Making Morphine; May Have To Lay Off Some 50 Workers
Billings Gazette -- CODY A federal judge has denied a last-minute request by Wyomings only pharmaceutical manufacturer to block a pending enforcement action that appears likely to force the company to cease manufacturing a potent painkiller.
Dense Bones Linked To Raised Risk For Prostate Cancer, National Institute on Aging and Johns Hopkins University School of Medicine Study
New Kerala -- Washington, July 29 : A new study has found that men, who develop prostate cancer, tend to retain denser bones as they age than men who stay free of the disease.
Anacor Pharmaceuticals, Inc. to Receive $15 million payment from Glaxo
Business Week -- Anacor Pharmaceuticals said Thursday it will receive a $15 million payment from GlaxoSmithKline on a deal over a potential antibiotic.
Cell-of-Origin for Human Prostate Cancer Identified for First Time, University of California, Los Angeles (UCLA) Study
ScienceDaily (July 29, 2010) UCLA scientists have identified for the first time a cell-of-origin for human prostate cancer, a discovery that could result in better predictive and diagnostics tools and the development of new and more effective targeted treatments for the disease.
Knee, Hip Replacements May Aid Weight Loss: Mount Sinai School of Medicine Study
THURSDAY, July 29 (HealthDay News) -- Weight loss has been noted among patients who've had a knee or hip replacement, a new study says.
Protein Complex Helps Cancer Cells Fight Platinum-Based Drugs By Fixing DNA Cross-Links, University of Texas MD Anderson Cancer Center and Zhejiang University Pharmaceutical Study
Life Science World -- HOUSTON - Researchers have discovered an enzyme crucial to a type of DNA repair that also causes resistance to a class of cancer drugs most commonly used against ovarian cancer.
Fluorescent Biosensor to Aid in Drug Development, Carnegie Mellon University Study
July 30, 2010 DNA India -- Carnegie Mellon researchers have come up with a new fluorescent biosensor that could aid in the development of an important class of drugs that target a crucial class of proteins called G protein-coupled receptors (GPCRs).
Geron Corporation Gets Human Trial Nod For Spinal Cord Therapy; FDA Lifts Clinical Hold On Human Trial Application
MENLO PARK, Calif., Jul 30, 2010 (BUSINESS WIRE) -- Geron Corporation /quotes/comstock/15*!gern/quotes/nls/gern (GERN 5.38, 0.58, 12.08%) announced today that the U.S. Food and Drug Administration (FDA) has notified the company that the clinical hold placed on Geron's Investigational New Drug (IND) application has been lifted and the company's Phase I clinical trial of GRNOPC1 in patients with...
Australian Watchdog Clears Novartis AG Bid For Alcon, Inc.
MELBOURNE July 29 (Reuters) - Australia's competition watchdog cleared Novartis AG's (NOVN.VX) planned buyout of Alcon Laboratories (ACL.N), after Novartis agreed to sell one of Alcon's products to eye care company Bausch & Lomb in Australia.
Scientists Post Lower Speed Limit For Cell-Signaling Protein Assembly, Michigan State University Study
EurekAlert! -- EAST LANSING, Mich. The apparently random self-assembly of molecular threads into the proteins that make the body work is far less frantic than previously thought, Michigan State University scientists say. That discovery could be a key to help unlock the nature of some diseases.
FDA Finds Problems At Sanofi-Aventis (France) Vaccine Plant
WASHINGTON (Reuters) - Sanofi-Aventis failed to follow proper manufacturing procedures at a vaccine plant in France, U.S. regulators said in a letter released on Thursday.
Angiotech Pharmaceuticals, Inc. Loss Widens As Royalties Slow
TORONTO July 30 (Reuters) - Angiotech Pharmaceuticals Inc (ANP.TO) said its second-quarter loss widened on Friday as royalty payments from its marketing partners slowed.
FDA Considering Changes To Risky Drug Safeguards
WASHINGTON (Reuters) - Safeguards to protect patients from risky drugs should have less paperwork and more consistency, drugmakers and pharmacy representatives said this week during a U.S. Food and Drug Administration meeting.
Sanofi-Aventis (France) Board Said to Support Genzyme Corporation Bid of Up to $18.7 Billion
Bloomberg -- Sanofi-Aventis SA Chief Executive Officer Chris Viehbacher has support from his board of directors to offer as much as $70 a share for Genzyme Corp., or about $18.7 billion, said three people with knowledge of the situation.
BioNJ Study: Biotech Employment Grew Despite Downturn
Philadelphia Business Journal -- The number of employees working at New Jersey biotechnology companies increased by 50 percent in the last three years, according to a survey conducted by BioNJ and Ernst & Young.
FDA Advisory Committee Recommends Approval of AstraZeneca PLC's Brilinta (Ticagrelor) for Acute Coronary Syndromes; Lifts Forecast Due to Ruling
WILMINGTON, Del., July 28 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE:AZN - News) today announced that the US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended the FDA approve AstraZeneca's investigational drug ticagrelor for the reduction of thrombotic events in patients with Acute Coronary Syndromes (ACS).
The review by the Advisory Committee...
Patients 'Could Grow New Joints', Columbia University, University of Missouri And Clemson University Study
Press Association -- People with knee or hip problems could in future "grow" their own replacement joints using their own stem cells, scientists have said.
Leap Forward In Efforts To Develop Treatments For Huntington's Disease, Buck Institute for Age Research Study
Medical News Today -- Scientists at the Buck Institute for Age Research have discovered that a particular family of enzymes are involved in the breakdown of proteins that modify the production of toxic fragments that lead to the pathology of Huntington's disease. These enzymes, matrix metalloproteinases (MMPs), provide new targets for drug therapies for the disease - targets that have already been...
Super-Sizing A Cancer Drug Minimizes Side Effects, Harvard University And Massachusetts Institute of Technology (MIT) Study
Physorg -- One of the first chemotherapy drugs given to patients diagnosed with cancer especially lung, ovarian or breast cancer is cisplatin, a platinum-containing compound that gums up tumor cells DNA. Cisplatin does a good job of killing those tumor cells, but it can also seriously damage the kidneys, which receive high doses of cisplatin because they filter the blood.
Shionogi Inc. Announces FDA Approval of CUVPOSA for the Treatment of Chronic Severe Drooling in Pediatric Patients With Neurologic Conditions
FLORHAM PARK, N.J., July 29 /PRNewswire/ -- Shionogi Inc., a U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. Food and Drug Administration approval of CUVPOSA (glycopyrrolate), the first liquid treatment for patients ages 3-16 who suffer from chronic severe drooling associated with neurologic conditions such as cerebral palsy. CUVPOSA was designated an Orphan Drug by the...
Breaching the Blood-Brain Barrier To Create Powerful New Tools for Fighting Cancer, Rensselaer Polytechnic Institute Study
Rensselaer Polytechnic Institute -- One of the human bodys most powerful defensive tools, the blood-brain barrier is a chemical labyrinth that prevents toxins and viruses in the bloodstream from reaching the brain. This foolproof security system, however, limits the ability of physicians to deliver drugs directly to the brain, making it difficult to treat brain tumors. Researchers at Rensselaer Polytechnic...
Alzheimer's Unlocked: New Keys To A Cure
New Scientist -- Attempts to treat the world's most common form of dementia may have been attacking its symptoms, not its root cause.
An HPV Vaccine Cheap Enough for the Developing World? Could Be According to Duke University Researchers
ScienceDaily (July 29, 2010) Vaccine manufacturers in India and other developing countries may be able to produce a lower-cost HPV vaccine in spite of the complicated array of patent protections on the technology, say researchers at the Duke Institute for Genome Sciences & Policy. At a cost of at least $300 for the three-dose regimen, the blockbuster HPV vaccines, including Gardasil from Merck and...
Abbott Laboratories's SIMCOR(R) (Niacin Extended-Release/Simvastatin ) Receives FDA Approval for New Dosage Strengths
ABBOTT PARK, Ill., July 28 /PRNewswire-FirstCall/ -- Abbott (NYSE:ABT - News) today received U.S. Food and Drug Administration (FDA) approval for two new dosage strengths of SIMCOR, a cholesterol medication. The new SIMCOR dosage strengths combine 40 mg of simvastatin the most commonly prescribed dose of simvastatin with either 500 mg or 1,000 mg of niacin extended-release. SIMCOR is the first...
Allergan Inc. Eye Drug Wins EU OK For Fluid Buildup
NEW YORK, July 28 (Reuters) - Allergan Inc (AGN.N) on Wednesday said its drug Ozurdex has become the first drug in Europe approved to treat a eyesight-endangering condition in which fluid builds up in the retina because of a clogged vein.
Omeros Corporation Secures $40 Million Committed Equity Financing Facility
SEATTLE, July 29 /PRNewswire-FirstCall/ -- Omeros Corporation (Nasdaq:OMER - News) today announced that it has secured a committed equity financing facility under which it may sell up to $40 million of its shares of common stock to Azimuth Opportunity, Ltd. (the "investor") over a 24-month period. Omeros is not obligated to use the facility and remains free to enter into and consummate other equity...
Aptuit, Inc. and Siena Biotech S.p.A. Announce Strategic Relationship in Italy; Takes Minor Slice of Italian R&D Operations
GREENWICH, Conn. & SIENA, Italy, Jul 29, 2010 (BUSINESS WIRE) -- Aptuit, Inc., and Siena Biotech S.p.A., today announced a strategic partnership in which Siena Biotech will take a minority stake in Aptuit's Italian operations in Verona, Italy, and Aptuit will become a provider of choice for Siena Biotech's development pipeline. Under the agreement Aptuit and Siena Biotech will work collaboratively...
Isis Pharmaceuticals, Inc. Earns $5 Million Milestone Payment From GlaxoSmithKline for Designation of a Development Candidate to Treat an Undisclosed Rare and Serious Disease
CARLSBAD, Calif., July 29 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq:ISIS - News) announced today that it has earned a $5 million milestone payment from GlaxoSmithKline (NYSE:GSK - News) related to the designation as a development candidate of a drug to treat an undisclosed rare and serious disease. Isis will develop the drug to Phase 2 proof-of-concept, at which time GSK has the...
Immunotherapy Shows Benefit in Prostate Cancer, Dana-Farber Cancer Institute Study
MedPage Today -- A cellular immunotherapy appears to prolong survival among men with metastatic, castration-resistant prostate cancer, researchers reported.
Test Predicts Novartis AG's Kinase Inhibitor Resistance in CML, Hokkaido University Study
MedPage Today -- A novel laboratory test may accurately distinguish which chronic myeloid leukemia (CML) patients will develop resistance to imatinib (Gleevec), researchers said.
CMP Therapeutics Appoints Dr. Neill Moray Mackenzie as CEO
LONDON, July 29, 2010 /PRNewswire/ -- CMP Therapeutics (CMPT) is pleased to announce the appointment of Dr Neill Moray Mackenzie to the role of Chief Executive Officer. Dr Mackenzie brings to CMPT a long record of executive board level management within the biotechnology and pharmaceutical industries at companies including Cambridge Genetics Ltd, Oxford Biomedica plc (an LSE listed company), Avidex...
Kangmei Pharma Invests $44 Million In 2 TCM Companies
July 29, 2010 -- Kangmei Pharmaceutical will purchase the pharmaceutical assets of two TCM companies from the Langzhong government in Sichuan province: Sichuan Tengwangge Pharmaceutical and Sichuan Baoning Pharmaceutical. The company will invest 300 million RMB ($44 million) in Langzhongs healthcare sector in the next two years. More details....
Stock Symbol: (SHEX: 600518)
CT Atlantic AG Announces Appointment of Michael Hocker To CEO
Schlieren, Switzerland, July 29, 2010 / b3c newswire / - CT Atlantic AG, a biotechnology company focused on cancer treatment by human-derived antibodies, announced the appointment of Michael Hcker to CEO. In addition, Cara Lerner has been appointed to COO.
Michael Hcker brings a strong background in translational medicine and clinical oncology together with significant experience as pharmaceutical...
Grifols H1 Sales Meet Forecasts, Net Profit Misses
Reuters -- Spain's Grifols (GRLS.MC), embroiled in a $3.4 billion takeover bid to become the world's third-largest haemoderivatives maker, posted a 3.7 percent rise in first-half sales, helped by strength at its Bioscience division.
Celgene Earnings Top Expectations, Shares Jump
SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG - News):
2010 Second Quarter Financial Results Year-Over-Year
* Non-GAAP Total Revenue Increased 36 Percent to $850 Million; GAAP Total Revenue $853 Million * Global REVLIMID Net Product Sales Increased 48 Percent to $587 Million * Global VIDAZA Net Product Sales Increased 43 Percent to $132 Million...
Eli Lilly and Company Loses Appeal in Gemzar Patent Case
WSJ -- A federal appeals court ruled Wednesday that an Eli Lilly Co. patent for anti-cancer drug Gemzar is invalid, a decision that may clear the way for generic competition to the drug late this year.
Sanofi-Aventis (France) Q2 Net up 61 Percent
Forbes -- Drugmaker Sanofi-Aventis SA said net profit rose 61 percent to euro1.7 billion ($2.2 billion) in the second quarter, thanks to lower restructuring costs, but warned that earnings may fall for the full year.
Wyeth and Waste Management Firm Face Eur 12 Million in Fines
Irish Times -- A LEADING pharmaceutical company and one of its contractors could face fines of up to 12.7 million each for breaches of waste management laws, Dublin Circuit Criminal Court has heard.
Talecris Biotherapeutics Q2 Profit Beats Street
RESEARCH TRIANGLE PARK, N.C., July 29 /PRNewswire-FirstCall/ -- Talecris Biotherapeutics Holdings Corp. ("Talecris") (Nasdaq:TLCR - News) today announced its financial results for the three and six months ended June 30, 2010 and filed its 2010 Form 10-Q with the U.S. Securities and Exchange Commission (SEC).
Second quarter 2010 net revenue increased by $27.3 million or 7.3% to $402.8 million...
BioPharm Executive: Firing Slows, but Lilly Fans the Flames
Astellas Pharma Inc. to Pay $295 Million to Extend License of Regeneron Pharmaceuticals, Inc.'s VelocImmune(R) Antibody Technology Through 2023
Trius Therapeutics Set to go Public This Week
Pfizer Inc.'s Viagra Weighed by U.S. FDA for Children With Rare Lung Disorder
One Molecule, Many More Insulin-Producing Cells To Treat Diabetes, Says University of Pittsburgh School of Medicine Team
Allos Therapeutics, Inc.'s Cancer Drug, Folotyn Extends Lung Cancer Survival
New Proteins That Regulate Blood Pressure, Flow Discovered, University of Pittsburgh School of Medicine Study
GlaxoSmithKline to Change Way it Pays U.S. Drug Sales Reps
Under the new system, bonuses for sales professionals who work directly with healthcare professionals and other customers will no longer be based on individual achievement of sales...
TARRYTOWN, N.Y. and TOKYO, July 28 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. ("Regeneron"; Nasdaq: REGN) and Astellas Pharma Inc. ("Astellas"; Headquarters: Tokyo, Japan; President & CEO: Masafumi Nogimori) announced today that Astellas has extended through 2023 the non-exclusive license agreement that allows Astellas to utilize Regeneron's VelocImmune technology in its internal research...
Bloomberg -- Development-stage biotechnology company Trius Therapeutics Inc. expects to raise up to $84 million this week in an initial public offering.
Bloomberg -- A form of Pfizer Inc.s erection drug Viagra, sold as the blood-pressure treatment called Revatio in adults, may be used for children with a rare lung disorder if U.S. regulators can agree on how to test it.
EurekAlert! -- PITTSBURGH, July 28 With a single stimulatory molecule, human insulin-producing beta cell replication can be sustained for at least four weeks in a mouse model of diabetes, according to researchers at the University of Pittsburgh School of Medicine in Diabetes, a journal of the American Diabetes Association.
Reuters -- Allos Therapeutics Inc said its cancer drug improved the survival of patients with advanced non-small lung cancer in a mid-stage trial.
ScienceDaily (July 27, 2010) Researchers at the University of Pittsburgh School of Medicine have identified key players in a little-known biochemical pathway that appears to regulate blood pressure. The findings, reported in the early online version of Cardiovascular Research, have evolved from studies conducted by Jeffrey S. Isenberg, M.D., Eileen M. Bauer, Ph.D., and their colleagues at Pitt's...
PHILADELPHIA, July 26 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE:GSK - News) today confirmed that it will implement a new system for evaluating and compensating its sales professionals beginning in 2011.
HemaQuest Raises $4M More, Boosting VC Round to $16M for Sickle Cell, Blood Disorders
Xconomy -- Another few months have gone by, and another few million bucks have arrived in the corporate treasury for HemaQuest Pharmaceuticals. The Seattle-based developer is announcing today it has raised $4 million for its experimental treatments for sickle cell anemia and other blood disorders.
Generex Biotechnology Corporation Provides Positive Update On Oral-Lyn(TM) Pivotal Phase III Trial
WORCESTER, Mass., July 28, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT - News), (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has now achieved 75% of the required number of per-protocol completers in its ongoing six month pivotal global Phase III study of Generex Oral-lyn(TM), the Company...
Bausch & Lomb Recall of PreserVision Eye Vitamin in the United States
Madison, NJ - infoZine - Bausch Lomb is conducting a voluntary recall of its PreserVision Eye Vitamin AREDS 2 Formula with Omega 3 soft gels, only available within the United States.
Illumina, Inc. Acquires Helixis, Inc. for Up to $105M, To Get Small, Low-Cost Genetic Analysis Tool
Xconomy -- San Diego-based Illumina has acquired an intriguing startup from southern California with a vision of putting low-cost genetic analysis systems on every biologists benchtop.
Merck & Co., Inc. Pays Settlements in 3,468 Vioxx Cases
Bloomberg -- Merck & Co. paid claims to the families of 3,468 users of its Vioxx painkiller who died of heart attacks or strokes, a court-appointed administrator told a judge today.
Marina Biotech, Inc. (Formerly Known as MDRNA, Inc.) Acquires RNA Delivery Assets of Novosom
BOTHELL, WA--(Marketwire - 07/28/10) - Marina Biotech, Inc. (NASDAQ:MRNAD - News) announced today that the Company has acquired the intellectual property of Novosom AG of Halle, Germany for its SMARTICLES liposomal-based delivery system in an all-stock transaction. The transaction further expands Marina's RNA delivery platform IP estate, which now includes DiLA2 delivery platform, tkRNAi (bacterial...
Vascular-Targeted Photodynamic Therapy for Localized Prostate Cancer, NYU Langone Medical Center Study
ScienceDaily (July 27, 2010) NYU Langone Medical Center has begun a clinical trial offering vascular-targeted photodynamic therapy to patients with localized prostate cancer. This novel, minimally invasive procedure uses a light-activated drug to deliver light energy waves by way of laser fibers in order to destroy prostate cancer cells.
UK's Recommends Roche Holding AG's MabThera For Leukemia
Dow Jones -- The U.K.'s National Institute for Health and Clinical Excellence, or NICE, Wednesday said it has recommended that Roche Holding AG's (ROG.VX) cancer drug MabThera be made routinely available on the publicly funded National Health Service to certain patients with chronic lymphocytic leukemia.
Tris Pharma, Inc. Announces Approval of First-Time Generic of Methylphenidate Hydrochloride Oral Solution With Six Months Exclusivity
MONMOUTH JUNCTION, N.J., July 28 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced that the US Food and Drug Administration (FDA) has approved a first-time generic of Methylphenidate Hydrochloride Oral Solution equivalent to brand name Methylin Oral Solution marketed by Shionogi Pharmaceuticals, Inc.
"Tris pursues...
Mylan Inc. Plans Eur 67 Million Solid-Dose Packaging Plant in Hungary
in-pharmatechnologist -- Mylan hopes new solid-dose packaging plant in Hungary will help it increase market share in Eastern Europe. The facility, a 10,000 sqm unit at the Komarom Industrial Park, will be refitted for tablet and capsule production. Mylan also plans to install blister packaging and bottling lines, as well as high potency drug handling capacity at the site over the next few years.
Dyax Corp. Posts Narrower-Than-Expected Q2 Loss
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX - News) today announced financial results for the second quarter ended June 30, 2010. Dyax will host a webcast and conference call at 10 a.m. (ET) this morning to review the financial results and corporate progress for the quarter.
* Patients currently in KALBITOR AccessSM program expanded to 264 * HAE patients with KALBITOR...
Alcohol Reduces the Severity of Rheumatoid Arthritis, University of Sheffield Study Finds
AFP -- PARIS Drinking alcohol may help reduce the severity of rheumatoid arthritis and cut the risk of developing the painful and crippling disease, a study published Wednesday has shown for the first time.
AstraZeneca PLC Bloodthinner, Brilinta Goes Before U.S. Experts Today
Reuters -- AstraZeneca Plc's experimental blood thinner goes before U.S. advisers on Wednesday, facing questions over why a trial of the potential blockbuster drug failed to cut heart attacks and deaths in North American patients.
Sanofi-Aventis (France), GlaxoSmithKline Eyes Troubled Genzyme Corporation; Rebuffs Bid
Reuters -- Genzyme Corp (GENZ.O) has turned down a bid to be acquired by French drugmaker Sanofi-Aventis (SASY.PA), Bloomberg reported on Monday, citing two people with knowledge of the matter.
Scientists Tap Into Antarctic Octopus Venom; Venom as Potential Resource For Drug Development, University of Melbourne Study
Sify -- Scientists have, for the first time, collected venom from octopuses in Antarctica, making a huge leap forward in our understanding of the properties of venom as a potential resource for drug-development.
Socialising 'Helps You Live Longer', Brigham Young University Study
Medical News Today -- A new study from the US suggests that social interaction should be considered an important factor for extending lifespan, on a par with other health and lifestyle factors, to the extent that low social interaction harms longevity as much as alcoholism and smoking, has more impact than lack of exercise, and is twice as harmful as obesity.
Morphine Blocks Tumor Growth, University of Minnesota Study
Physorg -- Current research suggests that taking morphine can block new blood vessel and tumor growth. The related report by Koodie et al, "Morphine suppresses tumor angiogenesis through a HIF1a/p38MAPK pathway," appears in the August 2010 issue of the American Journal of Pathology.
Protein Identified That Can Result in Fragile Bones, Medical College of Georgia Study
EurekAlert! -- AUGUSTA, Ga. Too little of a protein called neogenin results in a smaller skeleton during development and sets the stage for a more fragile bone framework lifelong, Medical College of Georgia researchers report.
EMD Serono, Inc., Merck KGaA Says FDA Grants Priority Review to Cladribine Tablets for the Treatment of Relapsing Forms of MS
ROCKLAND, Mass., July 28 /PRNewswire/ -- EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Cladribine Tablets as a therapy for relapsing forms of multiple sclerosis (MS).
The application also has been granted a Priority Review designation by the FDA...
US FDA Staff Mixed on AstraZeneca PLC Drug, Brilinta
Reuters -- U.S. reviewers gave mixed views on AstraZeneca Plc's (AZN.L) experimental blood thinner but the company's shares rose on investor optimism that an advisory panel will back the potential blockbuster drug.
Key Milestone Towards the Development of a New Clinically Useful Antibiotic, John Innes Centre Study
ScienceDaily (July 27, 2010) Scientists have identified the genes necessary for making a highly potent and clinically unexploited antibiotic in the fight against multi-resistant pathogens.
Toxicology Sinks Vernalis PLC, Biogen Idec, Inc. (Massachusetts)'s Parkinson's Drug
LONDON, July 16 (Reuters) - Vernalis (VER.L) has stopped development of a drug for Parkinson's disease that represented one of its main pipeline hopes, due to worries over adverse side effects, sending its shares 12 percent lower on Friday.
Extended Use of Anti-Clotting Drug Helps Some Bedridden Patients, Washington University School of Medicine Study Partially Funded By Sanofi-Aventis (France)
ScienceDaily (July 27, 2010) A treatment plan used to prevent potentially dangerous blood clots in recovering surgical patients can also benefit some patients immobilized by acute medical illness, doctors have found in a multi-institutional study.
Sinopharm Group and Merck & Co., Inc. Sign Statement of Mutual Intent to Boost China Presence
WHITEHOUSE STATION, N.J. & BEIJING, China--(BUSINESS WIRE)--Merck, known outside the U.S. and Canada as MSD, and Sinopharm (China National Pharmaceutical Group Corporation) today announced the signing of a statement of mutual intent. Under the statement, Sinopharm and Merck will cooperate on HPV vaccine and other mutually-selected vaccine products in China, and will also discuss the potential for promoting...
NovImmune SA Eyes IPO After Licensing Deal With Roche's Genentech
PLAN-LES-OUATES, Switzerland--(BUSINESS WIRE)--NovImmune, an antibody-focused research and development biotech company, announced today that it successfully entered into an exclusive licensing agreement with Genentech Inc. a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) for a proprietary anti-IL-17 fully human monoclonal antibody, and access to back-up antibodies. Recently, the IL-17 signaling...
Sanofi-Aventis (France) Asks U.S. Court to Block Sandoz, Inc.'s Generic Blood Thinner
Reuters -- Sanofi-Aventis (SASY.PA) on Monday asked a U.S. court to block the approval of a generic version of its widely used blood clot treatment Lovenox, arguing that federal regulators improperly approved the medicine last week.
Sanofi-Aventis (France) Alnwick Site Sale May Fund US Bid; 150 Jobs Secured
nebusiness.co.uk -- FRENCH drugs giant Sanofi-Aventis looks set to use some of the proceeds from the sale of its Northumberland plant to support a bid for an American drugs firm. Paris-based drug maker Sanofi-Aventis has made an informal approach to buy Genzyme Corp as it looks to move into the biotech arena, it has been reported.
Remembering To Forget: The Amnesic Effect Of Daydreaming, University of North Carolina And Florida State University Study
Medical News Today -- When your mind drifts, it's hard to remember what was going on before you stopped paying attention. Now a new study has found that the effect is stronger when your mind drifts farther - to memories of an overseas vacation instead of a domestic trip, for example, or a memory in the more distant past.
Prolias LLC Spins Out Prolias Technologies, Inc., a Life Sciences Research Reagent Supplier to the Cancer Research Community
FREDERICK, Md., July 27 /PRNewswire/ -- Prolias Technologies, Inc., a life science reagent and services company with a focus on supplying cancer researchers with the highest quality research reagents and unmatched customer service, announced today that it has spun out of Prolias, LLC and become its own entity.
Prolias Technologies, Inc. will strictly operate...
Great Lakes Pharmaceuticals, Inc. Raises $3.1 Million
PeHub -- Great Lakes Pharmaceuticals Inc., a Cleveland-based developer of an antimicrobial catheter lock solution, has raised $3.1 million in Series B funding. Charter Life Sciences led the round, and was joined by Early Stage Partners and return backers Everett Partners, Ohio TechAngel Fund and North Coast Angel Fund.
Ampio Pharmaceuticals, Inc. Announces Acquisition of DMI BioSciences, Inc.
GREENWOOD VILLAGE, Colo., July 27 /PRNewswire-FirstCall/ -- Ampio Pharmaceuticals, Inc. (OTC Bulletin Board:AMPE.ob - News) today announced it has finalized negotiations with the directors of DMI BioSciences, Inc. (DMI) to acquire DMI BioSciences, Inc. This acquisition will give Ampio access to all rights, royalties and patents associated with DMI's major assets, drugs for male sexual dysfunction...
Appeal Ruling Forces Rethink on Celgene's Vidaza for MDS
Pharmatimes.com -- Patients in the UK with myelodysplastic syndromes will be celebrating news that the National Institute for Health and Clinical Excellence has been ordered to reassess Celgenes Vidaza for the National Health Service.
Diex Research Grows into Montreal; Expects to Hire 10-20 Employees Within Next Year
sherbrookerecord.com -- While many businesses continue to plod along in what is still being labelled as a tough economy, a Sherbrooke company has managed to get ahead of the game on old-fashioned business sense, a great team and a golden reputation.
Sanofi-Aventis (France) and Merck & Co., Inc. Appoint as CEO for the New Animal Health Joint Venture
PARIS & WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Merck & Co., Inc. (NYSE: MRK - News) announced today that Raul E. Kohan will be appointed Chief Executive Officer of their proposed Animal Health joint venture. Sanofi-aventis and Merck - known as MSD outside the United States and Canada - intend to combine Merial with Intervet/Schering-Plough, to create...
Novartis Corporation Q2 Prompts Fresh Call for Higher Alcon, Inc. Bid
HUENENBERG, Switzerland--(BUSINESS WIRE)--The Alcon Independent Director Committee (the Committee) noted today that Alcon once again delivered strong earnings in the second quarter of 2010. Alcons 2Q 2010 Adjusted EPS of $2.22 per share represented a year-over-year growth rate of 14.4% and exceeded Wall Streets mean consensus estimate of $2.03 per share by 9.4%. Alcons strong EPS growth was driven...
New Compound Improves Obesity-Related Health Complications, National Institutes of Health (NIH) Study
ScienceDaily (July 26, 2010) An experimental compound appears to improve metabolic abnormalities associated with obesity, according to a preliminary study led by researchers at the National Institutes of Health.
Commonwealth Biotechnologies, Inc. Announces Appointment of as Chief Executive Officer
RICHMOND, Va.--(BUSINESS WIRE)--Commonwealth Biotechnologies, Inc. (CBI, CBTE.OB) today announced the appointment of Richard J. Freer, Ph.D. as Chief Executive Officer (CEO). He replaces Dr. Bill Guo who has served as Acting CEO since January of 2009.
Dr. Freer, one of the founders of the company, has served at various times as its Chairman of the Board, Director of Compliance, and most...
Teva Pharmaceutical Industries Limited Q2 Profit Beats Estimates, Sales in Line
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA - News) today reported results for the quarter ended June 30, 2010.
Second Quarter Highlights:
* Quarterly net sales of $3.8 billion, reflecting organic growth of 12%, compared to the comparable period in 2009. * Quarterly non-GAAP net income and non-GAAP EPS of $981 million and $1.08, up 32...
Muscle Gene May Provide New Treatments for Obesity And Diabetes, Rockefeller University Study
(PhysOrg.com) -- Skeletal muscle enables us to walk, run or play a musical instrument, but it also plays a crucial role in controlling disease. Rockefeller University scientists have now shown how a specific molecule in skeletal muscle regulates energy expenditure, a finding that may lead to new treatments for certain muscle diseases as well as diabetes, obesity and heart disease.
Infectious Prions Can Arise Spontaneously in Normal Brain Tissue, The Scripps Research Institute And University College London Study Shows
ScienceDaily (July 26, 2010) In a startling new study that involved research on both sides of the Atlantic, scientists from The Scripps Research Institute in Florida and the University College London (UCL) Institute of Neurology in England have shown for the first time that abnormal prions, bits of infectious protein devoid of DNA or RNA that can cause fatal neurodegenerative disease, can suddenly...
Antares Pharma, Inc. Announces Positive Top Line Results From Its Pivotal Phase 3 Study of Anturol Gel for the Treatment of Overactive Bladder
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NYSE Amex:AIS) announced today positive results from its Phase 3 study of AnturolTM Gel in patients with overactive bladder (OAB). The study met its primary endpoint of a statistically significant reduction in urinary incontinence episodes for both doses studied (56 mg daily or 84 mg daily, p0.028 and 0.033 respectively). An Open Label Extension...
PSA Screening Leads To Overdiagnosis, Often Aggressive Follow-Up, Cancer Institute of New Jersey Study
ABC News -- Many men being treated aggressively for low-grade prostate cancer -- particularly if it was detected during prostate-specific antigen (PSA) screening -- are unlikely to benefit from the intervention, a new study suggests.
Concern Over Animal Molecule In Drugs, University of California, San Diego (UCSD) Study
Medical News Today -- Researchers at the University of California, San Diego School of Medicine have discovered that a kind of sugar molecule common to chimpanzees, gorillas and other mammals but not found in humans provokes a strong immune response in some people, likely worsening conditions in which chronic inflammation is a major issue.
Onyx Pharmaceuticals, Inc. Announces Positive Top-Line Carfilzomib Data From Phase 2b Study
EMERYVILLE, Calif., July 26 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq:ONXX - News) today announced positive top-line results from the Phase 2b 003-A1 study of single-agent carfilzomib, a selective, next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma. In an independent review of the data, carfilzomib achieved an overall response rate ...
Pre-Exposure Prophylaxis Against HIV Found Safe, Centers for Disease Control and Prevention (CDC) Study
MedPage Today -- VIENNA -- Treating men at high risk of HIV with an antiretroviral drug -- as a preventive measure while they remain HIV-negative -- appears to be safe, a researcher said here.
Certain Epilepsy Drugs May Increase Risk of Suicide, Charite Medicine University Study
NEW YORK (Reuters Health) - While all epilepsy drugs carry a warning about an increased risk of suicidal behavior, it may only be certain newer medications that are connected to the hazard, a study published Monday suggests.
Dangers of Untreated Erectile Dysfunction, Study
ScienceDaily (July 26, 2010) Research carried out by a visiting professor at the University of Hertfordshire has found that up to six million European men fail to seek help for Erectile Dysfunction (ED) which could result in underlying cardiovascular disease going undetected.
Nasal Spray Vaccine for Meningitis In Pipeline, University of Liverpool Study
Independent -- Scientists are developing a nasal spray vaccine which could offer protection against meningitis and pneumonia, it was announced yesterday.
Ambit Biosciences Announces as Chairman and Chief Executive Officer
SAN DIEGO, July 26 /PRNewswire/ -- Ambit Biosciences Corporation (Ambit), a recognized global leader in kinase drug discovery and development, announced today that its Board of Directors has completed a thorough executive search and appointed Alan J. Lewis, Ph.D. as Chairman and Chief Executive Officer (CEO) of the Company. Dr. Lewis has been serving as Executive Chairman of Ambit since March 2...
Immune Design Corporation Raises $32 Million in Series B Financing
SEATTLE, July 26 /PRNewswire/ -- Immune Design Corp. (IDC), a privately held biotechnology company focused on developing novel vaccines and immunotherapies for infectious disease and cancer, announced today that it has secured $32 million in Series B financing. The round was led by ProQuest Investments and was joined by current investors: The Column Group, Versant Ventures, and Alta Partners. The...
Irradiating Stem Cell Niche Doubles Survival in Brain Cancer Patients, University of California, Los Angeles (UCLA) Study
ScienceDaily (July 22, 2010) Patients with deadly glioblastomas who received high doses of radiation that hit a portion of the brain that harbors neural stem cells had double the progression-free survival time as patients who had lower doses or no radiation targeting the area, a study from the Radiation Oncology Department at UCLA's Jonsson Comprehensive Cancer Center has found.
Rare And Common Genetic Variations Responsible For High Triglyceride Levels In Blood, University of Western Ontario Study
Physorg -- It can make blood look like cream of tomato soup. Patients with high levels of triglycerides in their blood, a disease called hypertriglyceridemia (HTG) face an increased risk for heart disease and stroke. HTG affects one in 20 people in North America and is also associated with obesity, diabetes and pancreatitis. Most people now understand the importance of LDL, the bad cholesterol and...
Dr. Reddy's Laboratories Ltd.'s Rules Out Stake Sale to GlaxoSmithKline
The Financial Express -- Dr Reddys Laboratories has said it would not dispose of its domestic formulations business in the backdrop of the recent market buzz that UK-based GlaxoSmithKline (GSK) is in talks with the Hyderabad-based firm for a 5% stake.
Returning Drugs Giant GlaxoSmithKline To Good Health
Telegraph -- The class was by invitation only. The criterion was running a company with more than $2bn (1.3bn) in sales. The location was Harvard. For Andrew Witty, it was where the plan was hatched.
Gilead Sciences, Inc. to Offer $2.2 Billion of Convertible Senior Notes; Company to Repurchase $1 Billion in Common Stock
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD - News) today announced its intention to offer, subject to market and other conditions, approximately $1.1 billion principal amount of convertible senior notes due 2014 and approximately $1.1 billion principal amount of convertible senior notes due 2016 to qualified institutional buyers pursuant to Rule 144A under the Securities...
XOMA (US) LLC Receives $750,000 Milestone Payment From AVEO Pharmaceuticals, Inc.
BERKELEY, Calif., July 26, 2010 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA - News), a leader in the discovery and development of therapeutic antibodies, announced receipt of a $750,000 milestone payment under its collaboration with AVEO Pharmaceuticals, Inc. (Nasdaq:AVEO - News). The milestone payment resulted from AVEO's recent initiation of a Phase 2 clinical trial to evaluate its AV-299 antibody...
FDA Grants Biovest International, Inc. Orphan Drug Status for Personalized Cancer Vaccine, BiovaxID(R), Targeting Mantle Cell Lymphoma
TAMPA, Fla. & MINNEAPOLIS--(BUSINESS WIRE)--Biovest International, Inc. (OTCQB: BVTI) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BiovaxID, Biovests personalized cancer vaccine, for a second lymphoma indication: mantle cell lymphoma. Mantle cell lymphoma is an aggressive and lethal B-cell blood cancer for which there is no current consensus...
National Institutes of Health (NIH) Develops Projects to Fight Rare Diseases
Wall Street Journal -- A government program focusing on rare diseases has launched five pilot projects that are taking the National Institutes of Health in a new direction: developing drugs.
FDA Approves Daiichi Sankyo, Inc.'s Tribenzor, A New Three-In-One Combination Product for the Treatment of High Blood Pressure
PARSIPPANY, N.J., July 26 /PRNewswire/ -- Daiichi Sankyo, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved TRIBENZOR (olmesartan medoxomil, amlodipine, hydrochlorothiazide), a new three-in-one combination product taken once-daily for the treatment of hypertension in patients who are not adequately controlled on any two of the following antihypertensive drug classes: angiotensin...
Cerenis Therapeutics, Inc. Raises $51.7 Million in Series C Financing and Wins $13.8 Million from French Government
TOULOUSE, France & ANN ARBOR, Mich.--(BUSINESS WIRE)--Cerenis Therapeutics SA (Cerenis), a biopharmaceutical company specializing in the research and development of novel therapies based on the metabolism of HDL (the good cholesterol) to treat cardiovascular and other metabolic diseases, announced today it has raised 40 million in the first close of its series C financing. In this round 20 million...
New National Institutes of Health (NIH) Grants Could Make Washington Hot Spot For Clinical Research
Washington Business Journal -- The Washington area could become one of the countrys go-to locales for clinical research, thanks to $58 million in National Institutes of Health grants now flowing to partnerships involving five D.C. hospitals and one of the regions largest health care systems.Work is under way to develop two centers to take advantage of the grants, awarded by the NIHs National...
Johnson & Johnson's HIV Drug Rilpivirine Passes Phase III Trials but Stumbles on Virologic Failure
SCRIP -- Johnson & Johnson's non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (TMC278) was safe and effective in two Phase III trials of treatment-nave HIV-patients, showed data presented last week at the 18th International AIDS conference in Austria. Both the ECHO and THRIVE studies...
Eisai Inc. and Pfizer Inc. Announce U.S. FDA Approval for New Higher-Dose Aricept(R) (donepezil HCl) 23 mg Tablet for the Treatment of Moderate-to-Severe Alzheimer's Disease
WOODCLIFF LAKE, N.J. & NEW YORK--(BUSINESS WIRE)--Eisai Inc. and Pfizer Inc [NYSE: PFE] announced today that the U.S. Food and Drug Administration (FDA) approved a new once-daily, higher-dose Aricept (donepezil HCl) 23 mg tablet for the treatment of moderate-to-severe Alzheimers disease (AD). Aricept 23 mg tablet offers another dosing option for patients with moderate-to-severe AD, for whom few treatments...
FDA Panel Opposes Plan to Tighten Use of Painkillers
New York Times -- An advisory committee for the Food and Drug Administration voted overwhelmingly on Friday to reject a plan proposed by the agency to reduce the misuse and abuse of long-acting painkillers like the drug OxyContin.
Sitting, Even After Workout, Can Cut Lifespan, American Cancer Society Study
CNN Health -- A new study debunks the theory that an hour of exercise a day is all you need to live a long life. Turns out, people who spend more time sitting during their leisure time have an increased risk of death, regardless of daily exercise.
Gene May Hold Key to Reducing Spread of Oral Cancers, University of Illinois Study
ScienceDaily (July 25, 2010) The spread of cancer cells in the tongue may be reduced if a gene that regulates cancer cell migration can be controlled, according to new research at the University of Illinois at Chicago.
Momenta Pharmaceuticals, Inc. Announces FDA Approval for First Generic Lovenox(R); Shares Surge
CAMBRIDGE, Mass., Jul 23, 2010 (GlobeNewswire via COMTEX) -- Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the U.S. Food and Drug Administration has granted marketing approval of the Abbreviated New Drug Application (ANDA) for enoxaparin sodium for injection filed by Sandoz. Developed under a collaboration...
'Sleep Control' Cells Allow Blind Mice To See, Johns Hopkins University Study
New Scientist -- WHAT happens when you take blind mice and see how they run? It turns out they can identify objects using receptors in the eye that were previously thought to have no role in forming images. Since humans possess the same receptors, the finding could point the way to giving blind people some ability to see.
Sickle Cell Treatment Developed At LA BioMed Enters Phase 3 Clinical Trial
Medical News Today -- An experimental treatment for sickle cell disease developed at the Los Angeles Biomedical Research Institute (LA BioMed) has entered Phase 3 clinical trials, David I. Meyer, PhD, LA BioMed president and CEO have announced .
Pfizer Animal Health Recalls Animal Drug, Terramycin
hpj.com -- Pfizer Animal Health is voluntarily recalling eight production lots of Terramycin (oxytetracycline HCI) Scours Tablets. Working in cooperation with the Food and Drug Administration, Pfizer Animal Health voluntarily initiated this recall when it was determined that certain lots manufactured by a third-party vendor contained an active pharmaceutical ingredient that was sourced from a facility...
Single Gene Could Be Key To A Baby's First Breath, CNRS - Facult?? de M??decine Study
New Scientist -- It's probably the first thing you ever did by yourself, but how did you know what to do? It's long been a mystery how newborn mammals draw their first breath after life in a fluid-filled womb and more importantly why this mechanism fatally fails in some individuals.
BioSpace.com Featured News and Stories
Charles River Laboratories (Massachusetts) and WuXi PharmaTech Co., Ltd. $1.6 Billion Deal Ended After Opposition
WILMINGTON, Mass., Jul 29, 2010 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. /quotes/comstock/13*!crl/quotes/nls/crl (CRL 34.00, 2.05, 6.42%) , a leading global provider of research models and associated services and of preclinical drug development services, today announced that it has mutually agreed with WuXi PharmaTech (Cayman) Inc. /quotes/comstock/13*!wx/quotes/nls/wx ...
Actient Pharmaceuticals LLC Inks Deal with UCB SA for Marketed Drugs with Global Sales of $53M
CHICAGO--(BUSINESS WIRE)--GTCR, one of the countrys leading private equity firms, announced today that Actient Pharmaceuticals, LLC has successfully completed a transaction to license and acquire six pharmaceutical products from UCB, Inc., a subsidiary of UCB SA, an international biopharmaceutical company based in Brussels, Belgium.The acquisition of the six on-market products is the first...
Orexigen Therapeutics, Inc. Obesity Pill Shows Promise in Phase III Study; Stock Rises 11.37% at 10:17AM EDT
SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) announced that results from its COR-I trial of Contrave were published online today in the journal Lancet. COR-I was the largest of the four, 56-week, Phase 3 trials supporting the New Drug Application for Contrave, currently under review by the U.S. Food and Drug Administration...
FDA Warns About Pneumonia Caused By Cubist Pharmaceuticals, Inc.'s Antibiotic Cubicin
WASHINGTON July 29 (Reuters) - U.S. health officials warned Thursday about the risk of pneumonia with Cubist Pharmaceuticals Inc's (CBST.O) flagship antibiotic.
Ruling May Force To Halt Making Morphine; May Have To Lay Off Some 50 Workers
Billings Gazette -- CODY A federal judge has denied a last-minute request by Wyomings only pharmaceutical manufacturer to block a pending enforcement action that appears likely to force the company to cease manufacturing a potent painkiller.
Anacor Pharmaceuticals, Inc. to Receive $15 million payment from Glaxo
Business Week -- Anacor Pharmaceuticals said Thursday it will receive a $15 million payment from GlaxoSmithKline on a deal over a potential antibiotic.
Geron Corporation Gets Human Trial Nod For Spinal Cord Therapy; FDA Lifts Clinical Hold On Human Trial Application
MENLO PARK, Calif., Jul 30, 2010 (BUSINESS WIRE) -- Geron Corporation /quotes/comstock/15*!gern/quotes/nls/gern (GERN 5.38, 0.58, 12.08%) announced today that the U.S. Food and Drug Administration (FDA) has notified the company that the clinical hold placed on Geron's Investigational New Drug (IND) application has been lifted and the company's Phase I clinical trial of GRNOPC1 in patients with...
Australian Watchdog Clears Novartis AG Bid For Alcon, Inc.
MELBOURNE July 29 (Reuters) - Australia's competition watchdog cleared Novartis AG's (NOVN.VX) planned buyout of Alcon Laboratories (ACL.N), after Novartis agreed to sell one of Alcon's products to eye care company Bausch & Lomb in Australia.
FDA Finds Problems At Sanofi-Aventis (France) Vaccine Plant
WASHINGTON (Reuters) - Sanofi-Aventis failed to follow proper manufacturing procedures at a vaccine plant in France, U.S. regulators said in a letter released on Thursday.
Angiotech Pharmaceuticals, Inc. Loss Widens As Royalties Slow
TORONTO July 30 (Reuters) - Angiotech Pharmaceuticals Inc (ANP.TO) said its second-quarter loss widened on Friday as royalty payments from its marketing partners slowed.
GlaxoSmithKline Begins Distribution of Flu Vaccine to U.S. Customers for 2010-2011 Flu Season
PHILADELPHIA, July 30 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) has released the first lots of FluLaval [Influenza Virus Vaccine] allowing distribution in the U.S. to begin for the 2010-2011 flu season. GSK anticipates distribution...
Sanofi Pasteur Begins Shipping Influenza Vaccine in U.S. for 2010-2011 Season
SWIFTWATER, Pa., July 30 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that shipping of the 2010-2011 formulation of its seasonal influenza vaccine Fluzone Influenza Virus Vaccine is underway in the U.S. This first shipment represents the first of more than 70 million doses of seasonal...
Mylan Inc. Announces Proposed Add-On Private Placement of its Senior Notes Due 2020
PITTSBURGH, July 29 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that it intends to privately place $300 million in aggregate principal amount of senior notes through a reopening of its Senior Notes due 2020, subject to market and other conditions. The notes are being offered as additional notes under an existing...
Speedus Corp. Announces Move to OTCQB Marketplace
FREEHOLD, N.J., July 30 /PRNewswire-FirstCall/ -- Speedus Corp. (OTCQB: SPDE) (the "Company") today announced that trading of shares of the Company's common stock will be transferred from The NASDAQ Stock Market to the OTCQB Marketplace beginning today, July 30, 2010. Investors will be able to easily trade the Company's stock in this...
Clinical and Laboratory Standards Institute Showcases StatisPro(TM)
WAYNE, PA--(Marketwire - July 29, 2010) -
, Fred Schwed mentions that the option market can be a good corrective when you're talking yourself into some investment idea. Take a look at it, he says, and you can see how many people are putting their own money down on the proposition that you might be wrong.